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With increasing use of clinical breast MRI and a plethora
of novel techniques and sequences for lesion characterisa-
tion, a standardised approach to lesion description and
reporting is increasingly important. This facilitates mean-
ingful research and audit, particularly in the context of
multicentre studies.
To this end the American College of Radiology has
recently published the 5th edition of the BI-RADS lexicon,
with revision of the MRI section including addition of new
descriptors, modification of others and deletion of some
that were rarely helpful in practice, such as ‘stippled’
enhancement [1]. Categories for fibroglandular volume are
now a to d, in line with the descriptors for mammography,
thus avoiding confusion with assessment category. The
degree of background parenchymal enhancement is now
purely descriptive, from none/minimal to marked. A new
descriptor is clustered rim enhancement (usually indicat-
ing DCIS). Non mass-like enhancement becomes non
mass enhancement, whereas ‘ductal’ enhancement
becomes linear. Overall the effect is of simplification and
consistency with the mammography and ultrasound
lexicons.
The lexicon highlights the importance of a structured
report, including the indication, scan technique, salient
findings and critically, an overall assessment with a clear
recommendation for further management. This approach
has been validated in a number of studies correlating the
assessment category with histopathological findings and/
or long-term follow-up [2,3].
Use of a standardised lexicon, modified in the light of
available evidence, has obviated some of the interpretative
challenges of breast MRI. Use of supplemental diffusion
weighted imaging may also be helpful [4]. Nonetheless,
technical and clinical challenges remain. Artefacts are
problematic, especially at 3T [5], and medical physics
support is essential for good quality diagnostic scans, espe-
cially at higher field strength.
Most importantly, it should be remembered that to date,
despite the recognised superiority of breast MRI over any
other modality for breast cancer detection and local sta-
ging, there is no hard evidence for improved patient out-
comes. Two randomised controlled trials and seven
comparative cohort studies have not shown any benefit for
preoperative MRI in terms of re-excision rates; rather,
there is a trend to higher mastectomy rates [6]. No convin-
cing beneficial effects have been demonstrated in terms of
in-breast tumour recurrence rates, disease-free survival or
overall survival. Regarding assessment of response to
neoadjuvant chemotherapy, MRI correlates better than
mammography or ultrasound with final pathology, but
false positive and negative studies are frequent, with
underestimation of the amount of residual disease in up to
30% and overestimation in around 20% of cases [7,8].
Though evidence is accruing that MRI may be helpful in
early response assessment, this is by no means standar-
dised and is heavily dependent on many factors, not least
tumour immunophenotype. Finally, though screening
breast MRI for women at high risk has approximately dou-
ble the sensitivity of mammography with encouraging
stage shift and high rates of node negativity, there is as yet
no evidence of a reduction in breast cancer mortality
[9,10].
This workshop will provide an update on the BI-RADS
lexicon and indications for breast MRI, with expert tuition
in hands-on analysis of case studies.
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